Neurocrine Biosciences Inc - NBIX STOCK NEWS

Neurocrine Biosciences (NASDAQ: NBIX) will present key data from its movement disorders and epilepsy programs at the American Academy of Neurology's 73rd Annual Meeting, scheduled virtually from April 17-22, 2021. Highlights include findings from the KINECT 4 Phase III study on INGREZZA for tardive dyskinesia and ONGENTYS efficacy in Parkinson's disease motor fluctuations. The data also emphasize the need for simplified treatment regimens for Parkinson's patients and present genetic insights into SCN8A-related epilepsy. These findings underscore Neurocrine's commitment to addressing significant neurological challenges.

Neurocrine Biosciences (Nasdaq: NBIX) will present at the Stifel 3rd Annual CNS Day on April 1, 2021, at 12:30 p.m. ET. The presentation will feature Eiry Roberts and Kyle Gano, focusing on the company’s advancements in neuroscience treatments. Investors can access the live webcast on the company's website, with a replay available approximately one hour after the event. Neurocrine is dedicated to developing treatments for neurological, endocrine, and psychiatric disorders, and has a robust portfolio that includes FDA-approved therapies for various conditions.

Neurocrine Biosciences (Nasdaq: NBIX) presented positive Phase II data for crinecerfont, an oral CRF1 receptor antagonist, at ENDO 2021. The study showed dose-dependent reductions in androstenedione, a CAH marker, while testosterone levels remained stable, indicating potential benefits for reproductive health. The presented data also included real-world evidence on CAH's impact from the I-CAH Registry and other studies. Neurocrine aims to demonstrate crinecerfont's effectiveness in upcoming Phase III studies while addressing glucocorticoid treatment limitations in classic congenital adrenal hyperplasia patients.

Neurocrine Biosciences (Nasdaq: NBIX) will present at the Oppenheimer 31st Annual Healthcare Conference on March 16, 2021, at 4:30 p.m. ET. CFO Matt Abernethy will lead the presentation. It will be available via live webcast on the company's website, with a replay accessible one hour post-event for approximately one month. Neurocrine is a biopharmaceutical company focused on neuroscience, offering FDA-approved treatments for conditions like tardive dyskinesia and Parkinson's disease, while engaging in various clinical programs.

On March 2, 2021, Neurocrine Biosciences (Nasdaq: NBIX) announced that its investigational drug, luvadaxistat (NBI-1065844), failed to meet the primary endpoint in the Phase II INTERACT study for treating negative symptoms of schizophrenia. Despite this, the drug showed promise in secondary endpoints related to cognitive assessment. The adverse events reported were consistent with prior studies. Neurocrine plans to collaborate with Takeda to explore further development paths following these results.

Neurocrine Biosciences (Nasdaq: NBIX) will present at the Cowen 41st Annual Health Care Conference on March 2, 2021, at 1:30 p.m. Eastern Time. CEO Kevin Gorman is set to deliver the presentation. A live webcast will be available on Neurocrine's website, with a replay accessible one hour after the event and archived for approximately one month. Neurocrine focuses on developing treatments for neurological and psychiatric disorders, with an array of FDA-approved therapies for conditions like tardive dyskinesia and Parkinson's disease.

Neurocrine Biosciences (NBIX) reported Q4 2020 revenues of $247.9 million, up from $244.1 million in Q4 2019. Full-year revenues reached $1.05 billion, a significant increase from $788.1 million in 2019. GAAP net income saw substantial growth, hitting $348 million or $3.58 per diluted share, largely due to a one-time tax benefit of $296 million. The company plans to invest $800-$850 million in combined R&D and SG&A for 2021, initiating eight mid-to-late-stage clinical studies. Notably, INGREZZA sales were $240 million for Q4 2020, reflecting a 1% increase compared to the previous year.

Neurocrine Biosciences (Nasdaq: NBIX) will report its fourth quarter and year-end 2020 financial results on February 4, 2021, after market close. A conference call and webcast will follow at 1:30 p.m. PT to discuss these results and provide a company update. Interested participants can join the call using the provided access numbers or through the company’s website. Neurocrine focuses on developing treatments for neurological and psychiatric disorders, boasting a portfolio that includes FDA-approved therapies.

Neurocrine Biosciences (Nasdaq: NBIX) reported preliminary net product sales for INGREZZA of approximately $240 million in Q4 2020 and $993 million for the full year. The company noted a 32% growth in total INGREZZA prescriptions in 2020, reaching 175,700 versus 132,700 in 2019. Key 2021 milestones include Phase III data for valbenazine in Huntington's disease expected in Q4 2021 and the initiation of several clinical studies. CEO Kevin Gorman highlighted the commitment to improving treatment accessibility for tardive dyskinesia patients.